About Evogene Ltd.
https://www.evogene.comEvogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform.
CEO
Ofer Haviv
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-07-25 | Reverse | 1:10 |
| 2013-11-19 | Reverse | 1:2 |
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
DELEK GROUP, LTD.
Shares:211.14K
Value:$221.7K
EIDELMAN VIRANT CAPITAL
Shares:117K
Value:$122.85K
UBS AG
Shares:50.85K
Value:$53.4K
Summary
Showing Top 3 of 3
About Evogene Ltd.
https://www.evogene.comEvogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $312K ▼ | $2.59M ▼ | $3.87M ▲ | 1.24K% ▲ | $0.44 ▲ | $-1.98M ▲ |
| Q2-2025 | $884K ▼ | $3.53M ▼ | $-4.46M ▼ | -504.75% ▼ | $-0.62 ▼ | $-2.55M ▼ |
| Q1-2025 | $2.44M ▲ | $4.57M ▼ | $-2.59M ▼ | -105.85% ▼ | $-0.38 ▼ | $-1.94M ▼ |
| Q4-2024 | $1.61M ▼ | $4.83M ▼ | $427K ▲ | 26.51% ▲ | $0.06 ▲ | $752K ▲ |
| Q3-2024 | $1.74M | $6.41M | $-7.63M | -438.51% | $-1.31 | $-3.64M |
What's going well?
The company reported a profit this quarter, and operating losses narrowed a bit. One-time gains from discontinued operations boosted the bottom line.
What's concerning?
Sales dropped sharply, margins turned negative, and the business is losing money on every sale. The profit is not from ongoing business, and costs are still much higher than revenue.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $15.96M ▲ | $26.09M ▼ | $6M ▼ | $1.14M ▲ |
| Q2-2025 | $11.69M ▲ | $33.93M ▼ | $21.55M ▼ | $-3.55M ▲ |
| Q1-2025 | $9.85M ▼ | $34.3M ▼ | $21.91M ▼ | $-3.65M ▼ |
| Q4-2024 | $15.31M ▼ | $39.86M ▼ | $25.03M ▼ | $-1.45M ▲ |
| Q3-2024 | $19.95M | $40.11M | $27.88M | $-4.34M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.05M ▼ | $-3.79M ▲ | $11.27M ▲ | $-10.64M ▼ | $-2.7M ▼ | $-3.8M ▼ |
| Q2-2025 | $-3.53M ▼ | $-7.52M ▼ | $-989K ▲ | $4.15M ▲ | $834K ▲ | $-2.3M ▲ |
| Q1-2025 | $-2.99M ▼ | $-5.18M ▲ | $-2.45M ▼ | $-159K ▼ | $-7.81M ▼ | $-5.3M ▲ |
| Q4-2024 | $-5K ▲ | $-5.21M ▼ | $8.76M ▲ | $440K ▼ | $3.98M ▲ | $-5.53M ▼ |
| Q3-2024 | $-8.22M | $-4.93M | $2.02M | $4.73M | $1.83M | $-5.06M |
CEO
Ofer Haviv
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-07-25 | Reverse | 1:10 |
| 2013-11-19 | Reverse | 1:2 |
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
DELEK GROUP, LTD.
Shares:211.14K
Value:$221.7K
EIDELMAN VIRANT CAPITAL
Shares:117K
Value:$122.85K
UBS AG
Shares:50.85K
Value:$53.4K
Summary
Showing Top 3 of 3